News

Gilead Sciences, Inc.'s Biktarvy has been approved by the FDA for the treatment of those with HIV-1.

Grifols receives approval from the FDA for a new higher potency formulation of HyperRAB rabies immune globulin for rabies post-exposure prophylaxis.

Should SIGA's drug be approved, it will be the first treatment available for the deadly disease.

The FDA grants Mesa Biotech Inc.'s Accula Flu A/Flu B test 510(k) clearance and CLIA waiver.

Contagion® celebrates its second year this month amid celebrations of bringing in its highest readership traffic to-date.

Researchers from the Wellcome Sanger Institute and collaborators find that a multidrug-resistant strain of malaria spread throughout Cambodia 5 years before clinical resistance was even reported.

Researchers from UT Health San Antonio find that exposing the gut to chlamydia protects against subsequent infection in the genital tract as well as other tissues.

A second hospital finds that the combination of a mechanical initial specimen diversion device (ISDD) and staff education resulted in about a decrease in the contamination of blood cultures.

An accredited dentist suggests that practiced care for the mouth and teeth could potentially help individuals during flu season.

Superbugs resistant to colistin – a last-resort antibiotic – may have a new foe in octapeptins, antibiotics discovered decades ago that recently have been found to be effective against multidrug-resistant gram-negative bacteria.

The vaccine candidate is ASP0113, which was in development to treat and prevent cytomegalovirus (CMV) in hematopoietic stem cell transplant recipients.

The Cystic Fibrosis Foundation has awarded Motif Bio with $120,000 that will fund in vitro testing for the development of iclaprim to benefit patients with cystic fibrosis who have lung infections.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

At one of the worst times, as hospitals are already over capacity with more influenza patients than ever before, the United States is battling an IV bag shortage.

In case you missed them, we've compiled a list of the latest US Food and Drug Administration (FDA) recalls posted this week.

The FDA has approved Allergan's sNDA to expand the approved use of AVYCAZ (ceftazidime and avibactam), to include the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible Gram-negative microorganisms.

The World Health Organization (WHO) released its first report on antibiotic resistance surveillance data.

Findings from a new National Institutes of Health study may have important implications for flu vaccine development.

The FDA grants 510(k) clearance to TECHLAB to market 2 noninvasive tests intended to aid in the diagnosis of campylobacteriosis.

An ongoing study aims to confirm that newer ART regimens are as safe for pregnant women living with HIV as they are for their non-pregnant counterparts.

E. Canadensis tapeworms may be under-recognized in the United States.

Emerging and neglected tropical diseases are on the rise in Texas, and now, a new paper explores what state health officials need to do in response.

Historically, postoperative pulmonary complications have been the most common serious adverse event following upper abdominal surgery, with incidence rates ranging from 10% to 50%.

Amid alleged tobacco investments, Brenda Fitzgerald has resigned from her position as director of the CDC.

A multinational team of investigators has revealed a link between conflict-induced displacement of people and the spread of HIV within Ukraine.

With about 1 million individuals getting herpes zoster each year in the United States, the best protection against the virus is vaccination.

As this season’s flu continues to drive patients to hospitals in droves, an IV bag shortage and tapped out staffing makes infection control particularly difficult.

The FDA grants Fast Track designation to TAK-426, Takeda’s purified, inactivated, alum-adjuvanted whole Zika virus vaccine candidate.